TACSTD2 and urothelial carcinoma: Despite the potential value of Trop-2 expression levels in affecting sensitivity to Trop-2-targeted therapy, current treatment guidelines do not require Trop-2 expression levels to be tested before the use of Trop-2-targeted ADCs for breast or uroepithelial carcinoma patients.